AGIO

The article highlights four high-risk, high-reward stocks: Agios Pharmaceuticals awaiting FDA approval for mitapivat to treat sickle cell disease; Navitas Semiconductor pivoting toward AI data centers and high-power chips; Joby Aviation developing eVTOL transportation services with autonomous capabilities; and Viking Therapeutics developing obesity drug VK2735 with potential in a multi-billion dollar market. All require patience but offer significant upside if their respective catalysts materialize.

Agios Pharmaceuticals' stock declined 29% over three months following the discontinuation of tebapivat across all indications after failing to demonstrate differentiation from existing treatments. With tebapivat no longer advancing, the company is increasingly dependent on mitapivat, which showed strong 259.3% year-over-year sales growth to $44.7 million in Q2 2026. However, intensifying competition from Novo Nordisk's etavopivat in the sickle cell disease market poses challenges as Agios awaits FDA approval for mitapivat in SCD by November 2026.

Agios Pharmaceuticals' mitapivat-based drugs (Pyrukynd and Aqvesme) generated $44.7 million in Q2 2026 revenue, up 259% year-over-year, driven by early thalassemia adoption. However, the discontinuation of pipeline drug tebapivat and intensifying competition from Novo Nordisk's etavopivat in sickle cell disease have made the company heavily dependent on mitapivat's commercial success.

Danaher Corporation reported Q3 adjusted EPS of $2.11, beating estimates by 9.9%, with revenues of $6.55 billion in line with expectations. The company raised its 2026 adjusted EPS guidance to $8.57-$8.62 and expects 2.5% core revenue growth. Diagnostics segment sales jumped 17% driven by acquisitions, though respiratory testing revenues declined significantly from $500M to $350M year-over-year.

Danaher Corporation is expected to report Q3 2026 revenues of $26.3 billion, up 8.2% year-over-year, driven by strength in Biotechnology, Diagnostics, and Life Sciences segments, plus the Masimo acquisition. However, rising input costs, product mix changes, and currency headwinds may pressure profits. The company has a positive Earnings ESP of +0.30% and Zacks Rank of 2 (Buy).